SRR8752370
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.550
- E2F_TARGETS+0.500
- G2M_CHECKPOINT+0.470
- ESTROGEN_RESPONSE_LATE+0.290
- ESTROGEN_RESPONSE_EARLY+0.270
- MYC_TARGETS_V1+0.270
- MITOTIC_SPINDLE+0.250
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.200
- WNT_BETA_CATENIN_SIGNALING+0.200
- UV_RESPONSE_UP+0.180
Top 10 suppressed
- PROTEIN_SECRETION-0.480
- INTERFERON_ALPHA_RESPONSE-0.300
- UV_RESPONSE_DN-0.290
- INTERFERON_GAMMA_RESPONSE-0.280
- ALLOGRAFT_REJECTION-0.270
- TGF_BETA_SIGNALING-0.270
- ANGIOGENESIS-0.260
- COAGULATION-0.260
- BILE_ACID_METABOLISM-0.250
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.250
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8518126 | — | E | 0.838 |
| 2 | SRR15030870 | — | — | 0.803 |
| 3 | SRR6013543 | — | cohortSQ1 | 0.802 |
| 4 | MNG715 | — | — | 0.799 |
| 5 | C3N-02434 | — | cohortSQ2 | 0.792 |
| 6 | 20020032.TNBC | — | E | 0.791 |
| 7 | C3N-01025 | — | cohortSQ2 | 0.769 |
| 8 | TCGA-77-8153-01A-11R-2403-07 | — | cohortSQ2 | 0.767 |
| 9 | SRR6013540 | — | cohortSQ2 | 0.765 |
| 10 | BS_8SKZ7BRN | low-grade glioma | — | 0.762 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.550 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.500 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.470 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.290 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.270 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.270 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.250 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.200 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.200 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.180 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.170 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.170 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.160 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.130 | Temsirolimus | — uncovered |
| P53_PATHWAY | 0.120 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.100 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.070 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.050 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.050 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.030 | Remibrutinib | — uncovered |